474706-36-0

Basic information

• Product Name: 4-Bromo-5-(4-fluorophenyl)-1(2)H-pyrazole
• Synonyms: 4-Bromo-5-(4-fluorophenyl)-1(2)H-pyrazole;4-BroMo-5-(4-fluorophenyl)-1H-pyrazole;4-bromo-3-(4-fluorophenyl)-1H-pyrazole
• CAS NO: 474706-36-0
• Molecular Formula: C₉H₆BrFN₂
• Molecular Weight: 241.0597432
• Mol File: 474706-36-0.mol

Chemical Properties

• Boiling Point: 361.5±27.0 °C(Predicted)
• Appearance: /
• Density: 1.643±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.75±0.50(Predicted)
• CAS DataBase Reference: 4-Bromo-5-(4-fluorophenyl)-1(2)H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-5-(4-fluorophenyl)-1(2)H-pyrazole(474706-36-0)
• EPA Substance Registry System: 4-Bromo-5-(4-fluorophenyl)-1(2)H-pyrazole(474706-36-0)

Safety Data

• Hazardous Substances Data: 474706-36-0(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
4-Bromo-5-(4-fluorophenyl)-1(2)H-pyrazole is used as a ligand in medicinal chemistry for its ability to interact with different biological targets such as receptors and enzymes. This interaction is crucial for the development of pharmaceuticals with specific therapeutic effects.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, 4-Bromo-5-(4-fluorophenyl)-1(2)H-pyrazole serves as a key intermediate in the synthesis of various organic compounds and pharmaceuticals. Its unique structure allows for the creation of new molecules with potential therapeutic properties, contributing to the advancement of drug discovery and development.
Used in Organic Chemistry:
4-Bromo-5-(4-fluorophenyl)-1(2)H-pyrazole is also utilized in organic chemistry as a building block for the synthesis of complex organic molecules. Its bromine and fluorine atoms, along with the pyrazole ring, provide opportunities for further functionalization and the creation of diverse chemical entities with potential applications in various fields.

Upstream product

• 154258-82-9 3-(4-fluorophenyl)-1H-pyrazole 

Downstream Products

• 1616235-69-8 3-bromo-6-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-2-amine 
• 1616235-11-0 6-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-N-(pyrimidin-2-yl)imidazo[1,2-b]pyridazin-2-amine 
• 1616235-12-1 1-(6-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)-3-phenylurea 
• 1616235-13-2 benzyl 6-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-2-ylcarbamate 
• 1616235-14-3 3-bromo-6-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)-N-(pyrimidin-2-yl)imidazo[1,2-b]pyridazin-2-amine 
• 1616235-43-8 N-(6-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)acetamide 
• 1616235-42-7 6-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-2-amine 
• 1616233-24-9 N-(6-(3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-2-yl)isonicotinamide 
• 863605-34-9 4-bromo-3-(4-fluorophenyl)-1-methyl-1H-pyrazole 
• 474706-42-8 4-bromo-3-(4-fluorophenyl)-1-trityl-1H-pyrazole 

Relevant articles and documents

PYRAZOLE SUBSTITUTED IMIDAZOPYRAZINES AS CASEIN KINASE 1 D/E INHIBITORS

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents.

NITROGENOUS FUSED?RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF

The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. Inparticular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, X represents a nitrogen-containing condensed aromatic heterocyclic group such as imidazo[1,2-a]pyridine, benzimidazole, quinazoline, quinoline, or 2,1-benzisoxazole and has (R4)n as substituent groups; Y represents a C3-8 cycloalkyl group, C4-8 cycloalkenyl group, 5- to 14-membered non-aromatic heterocyclic group, C6-14 aromatic hydrocarbon cyclic group or 5- to 14-membered aromatic heterocyclic group; n in (R4)n is 0, 1, 2 or 3, and Z groups independently represent (1) hydrogen atom, (2) amino group, (3) halogen atom, (4) hydroxyl group, (5) nitro group, (6) cyano group, (7) azido group, (8) formyl group, (9) hydroxyamino group, (10) sulfamoyl group, (11) guanodino group, (12) oxo group, (13) C2-6 alkenyl group, (14) C1-6 alkoxy group, (15) C1-6 alkylhydroxyamino group, (16) halogenated C1-6 alkyl group, (17) halogenated C2-6 alkenyl group, (18) (i) C3-7cycloalkyl group, (ii) C3-7cycloalkenyl group, (iii) 5- to 14-membered non-aromatic heterocyclic group, each of which may have one or more substituent groups Q, or (19) formula -M1-M2-M3, R1 represents (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) nitro group, (5) cyano group, (6) halogenated C1-6 alkyl group, (7) C2-6 alkyl group substituted with a hydroxyl or cyano group, (8) C2-6 alkenyl group, or (9) formula -L1-L2-L3, and R2 represents a hydrogen atom or a protecting group; and R3 represents a hydrogen atom, halogen atom, cyano group, amino group, C1-4 alkyl group or halogenated C1-4 alkyl group.